Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure

Current Medicinal Chemistry

Volumn 16, Issue 23, 2009, Pages 3028-3040

  Stratta, Piero ^a   Karvela, Eirini ^a   Canavese, Caterina ^a   Quaglia, Marco ^a   Lazzarich, Elisa ^a   Fenoglio, Roberta ^a   Pergolini, Patrizia ^a   Bellomo, Giorgio ^a   Cena, Tiziana ^a   Magnani, Corrado ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Anti xa activity; Low molecular weight heparin; Pharmacokinetics; Prophhylaxis; Renal failure; Structure function relationships; Thromboembolism; Unfractionated heparin

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; BLEEDING; BODY MASS; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PROTEIN INTERACTION; PROTHROMBIN TIME; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; FACTOR IX; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE; RISK; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 70349404307     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803105     Document Type: Review

References (92)

1. Hirsh, J.; Bauer, K.A.; Donati, M.B.; Gould, M.; Samama, M.M.; Weitz, J.I. Parenteral Anticoagulants American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008, 133, 141S-159S.
2. Geerts, W.H; Bergqvist, D.; Pineo, G.F.; Heit, J.A.; Samama, M.M.; Lassen, M.R.; Clifford, W.C. Prevention of Venous Thromboembolism American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, 2008, 133, 381S-453S.
3. Nutescu, A. Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches. Am. J. Health. Syst. Pharm., 2007, 64, S5-S13.
4. Kearon, C.; Kahn, S.R.; Agnelli, G.; Goldhaber, S.; Raskob, G.E.; Comerota, A.J. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 2008, 133, 454S-545S.
5. McLean, J. The thromboplastic action of cephalin. Am. J. Physiol., 1916, 41, 250-257.
6. Geerts, W.H.; Jay, R.; Code, K.; Chen, E.; Szalai, J.P.; Saibil, E.A.; Hamilton, P.A. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxes against venous thromboembolism after major trauma. N. Engl. J. Med., 1996, 335, 70-707.
7. Hirsh, J.;Warkentin, T.E.; Shaughnessy, S.G.; Anand, S.S.; Halperin, J.L.; Raschke, R.; Granger, C.; Ohman, E.M.; Dalen,. JE. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, 119, 64S-94S.
8. Hirsh, J.;Raschke, R. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Heparin and Low-Molecular-Weight Heparin. Chest, 2004, 126, 188S-203S.
9. Hirsh, J.;O'Donnell, M.; Eikelboom, J.W. Contemporary reviews in cardiovascular medicine beyond unfractionated heparin and warfarin current and future advances. Circulation, 2007, 116, 552-560.
10. Olson, S.T.; Swanson, R.; Raub-Segall, E.; Bedsted, T.; Sadri, M.; Petitou, M.; Hérault, J.P.; Herbert, J.M.; Björk, I. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb. Haemost., 2004, 92, 929-39.
11. Lobo, B.L. Use of newer anticoagulants in patients with chronic kidney disease. Am. J. Health-System Pharmacy, 2007, 64, 2017-2026.
12. Fox, K.A.; Bassand, J-P.; Mehta, S.R.; Wallentin, L.;Theroux, P.; MD; Piegas, L.S.; Valentin, V.;Moccetti, T.; Chrolavicius, S.; Afzal, R.; Yusuf, S., on behalf of the OASIS 5 Investigators Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndromes. Ann. Int. Med., 2007, 147, 304-310.
13. Bara, L.; Billaud, E.; Grammond, A.; Kher, A.; Samama, M.Comparative pharmacokinetics of low molecular weight heparin and unfractionated heparin after intravenous and subcutaneous administration. Thromb. Res., 1985, 39, 63-636.
14. Barzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim. Biophys. Acta, 1985, 845, 196-203.
15. Sobel, M.; McNeill, P.M.; Carlson, P.L.; Kermode, J.C.; Adelman, B.; Conroy, R.; Marques, D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J. Clin. Invest., 1991, 87, 1787-1793.
16. Young, E.; Prins, M.H.; Levine, M.N.; Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb. Haemost., 1992, 67, 639-643.
17. Frydman A. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis, 1996, 26, S24-38.
18. Laposata, M.;Green, K.; Van Cott, E.M.; Barrowcliffe, T.W.; Goodnight, S.H.; Sosolik, R.C. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch. Pathol. Lab. Med., 1998, 122, 799-807.
19. Walenga, J.M.; Hoppensteadt, D.A. Monitoring the new antithrombotic drugs. Semin. Thromb. Hemost., 2004, 30, 683-695
20. Handeland, G.F.;Abildgaard, U.; Holm, H.A.; Arnesen, K.E. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Eur. J. Clin. Pharmacol., 1990, 39, 107-112.
21. Samama, M.M. Contemporary laboratory monitoring of low molecular weight heparins. Clin. Lab. Med., 1995, 15, 119-123.
22. Boneu, B. Low molecular weight heparin therapy: Is monitoring needed. Thromb. Haemost., 1994, 72, 330-334.
23. Raschke, R.A.; Gollihare, B.; Peirce, J.C. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch. Intern. Med., 1996, 156, 645-649.
24. Raschke, R.A.; Hertel, G. Clinical use of the heparin nomogram. Arch. Intern. Med., 1991, 15, 2318-2321.
25. Hirsh, J.; Dalen, J.; Guyatt, G. American College of Chest Physicians. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest, 2001, 119, 1S-2S.
26. Olson, J.D.; Arkin, C.F.; Brandt, J.T.; Cunningham, M.T.; Giles, A.; Koepke, J.A.; Witte, D.L. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy. Arch. Pathol. Lab. Med., 1998, 122, 782-798.
27. Marci, C.D.; Prager, D. A review of the clinical indications for the plasma heparin assay. Am. J. Clin. Pathol., 1993, 99, 546-550.
28. Cirisano, F.D.; Lee, S.; Greenspoon, J.S. Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report. J. Reprod. Med., 1996, 41, 191-194.
29. Smogorzewska, A.; Brandt, J.T.; Chandler, W.L.; Cunningham, M.T.; Hayes, T.E.; Olson, J.D.; Kottke-Marchant, K.; Van Cott, E.M. Effect of fondaparinux on coagulation assays: Results of College of American Pathologists proficiency testing. Arch. Pathol. Lab. Med., 2006, 130, 1605-1611.
30. Wysowski, D.K.; Talarico, L.; Bacsanyi, J.; Botstein, P. Spinal and epidural hematoma and low-molecular-weight heparin. N. Engl. J. Med., 1998, 338, 1774-1775.
31. Busby, L.T.; Weyman, A.; Rodgers, G.M. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am. J. Hematol., 2001, 67, 54-56.
32. Visger, J.V.; Magee, C. Low molecular weight heparins in renal failure. J. Nephrol., 2003, 16, 914-916.
33. Shullo, M.A.; Rose, M.L.; Vivas, C.; Jordan, M.L.; Scantlebury, V.P.; Jain, A.; Corry, R.J.; Fung, J.J.; McCauley, J.; Johnston, J.; Shapiro, R. Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants. Pharmacotherapy, 2002, 22, 184-187.
34. Farooq, V.; Hegarty, J.; Chandrasekar, T.; Lamerton, E.H.; Mitra, S.; Houghton, J.B.; Kalra, P.A.; Waldek, S.; O'Donoghue, D.J.; Wood, G.N. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am. J. Kidney Dis., 2004, 43, 531-537.
35. Gerlach, A.T.; Pickworth, K.K.; Seth, S.K.; Tanna, S.B.; Barnes, J.F. Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency. Pharmacotherapy, 2000, 20, 771-775.
36. Spinler, S.A.; Inverso, S.M.; Cohen, M.; Goodman, S.G.; Stringer, K.A.; Antman, E.M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am. Heart J., 2003, 146, 33-41.
37. Monreal, M.; Falgá, C.; Valle, R.; Barba, R.; Bosco, J.; Beato, J.L.; Maestre, A. Venous Thromboembolism in Patients with Renal Insufficiency: Findings from the RIETE Registry. Am. J. Med., 2006, 119, 1073-1079.
38. Cohen, M.; Demers, C.; Gurfinkel, E.P.; Turpie, A.G.; Fromell, G.J.; Goodman, S.; Langer, A.; Califf, R.M.; Fox, K.A.; Premmereur, J.; Bigonzi, F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N. Engl. J. Med., 1997, 337, 447-452
39. Gould, M.K.; Dembitzer, A.D.; Doyle, R.L.; Hastie, T.J.; Garber, A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann. Intern. Med., 1999, 130, 800-809.
40. Magee, K.D.; Sevcik, W.; Moher, D.; Rowe, B.H. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database Syst. Rev., 2003, (1): CD002132.
41. Antman, E.M.; Cohen, M.; Radley, D.; McCabe, C.; Rush, J.; Premmereur, J.; Braunwald, E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation, 1999, 100, 1602-1608
42. Baglin, T.; Barrowcliffe, T.W.; Cohen, A.; Greaves, M. British Committee for Standards in Haematology Guidelines on the use and monitoring of heparin. Br. J. Haematol., 2006, 133, 19-34.
43. Samama, M.M.; Grigoris, T.G. Comparative Pharmacokinetics of LMWHs Service d'Hématologie Biologique, Hôpital Hôtel-Dieu de Paris, Paris, France. Semin. Thromb. Hemost., 2000, 26, 031-038.
44. Brophy, D.F.; Wazny, L.D.; Gehr, T.W.; Comstock TJ.; Venitz J. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy, 2001, 21, 169-174.
45. Phillips, K.W.; Dobesh, P.P.; Haines, S.T. Considerations in using anticoagulant therapy in special patient populations. Am. J. Health-System Pharmacy, 2008, 65, S13-S21.
46. Nagge, J.; Crowther, M.; Hirsh, J. Is impaired renal function a contraindication to the use of low- molecular-weight heparin? Arch. Intern. Med., 2002, 162, 2605-2609.
47. Cadroy, Y.; Pourrat, J.; Baladre, M.F.; Saivin, S.; Houin, G.; Montastruc, J.L.; Vernier, I.; Boneu, B. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb. Res., 1991, 63, 385-390.
48. Sanderink, G.J.; Guimart, C.G.; Ozoux, M.L.; Jariwala, N.U., Shukla, U.A.; Boutouyrie, B.X. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb. Res., 2002, 105, 225-231.
49. Bazinet, A.; Almanric, K.; Brunet, C.; Turcotte, I., Martineau, J.; Caron, S.; Blais, N.; Lalonde, L. Dosage of enoxaparin among obese and renal impairment patients, Thromb. Res., 2005, 116, 41-50.
50. Chow, S.L.; Zammit, K.; West, K.; Dannenhoffer, M.; Lopez-Candales, A.Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J. Clin. Pharmacol., 2003, 43, 586-590.
51. Lim, W.; Dentali, F.; Eikelboom, J.W.; Crowther, M.A. Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency. Ann. Int. Med., 2006, 144, 673-684.
52. Cestac, P.; Bagheri, H.; Lapeyre-Mestre, M.; Sié, P.; Fouladi, A.; Maupas, E.; Léger, P.; Fontan, B.; Massip, P.; Montastruc, J.L. Utilisation and safety of low molecular weight heparins: Prospective observational study in medical inpatients. Drug Saf., 2003, 26, 197-207.
53. Levine, M.N.; Planes, A.; Hirsh, J.; Goodyear, M.; Vochelle, N.; Gent, M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb. Haemost., 1989, 62, 940-944.
54. Becker, R.C.; Spencer, F.A.; Gibson, M., Rush, J.E.; Sanderink, G.; Murphy, S.A.; Ball, S.P.; Antman, E.M. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am. Heart. J., 2002, 143, 753-759.
55. Goudable, C.; Saivin, S.; Houin, G.; Sie, P.; Boneu, B.; Tonthat, H.; Suc, J.M. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron, 1991, 59, 543-545.
56. Mismetti, P.; Laporte-Simitsidis, S.; Navarro, C.; Sié, P.; d'Azemar, P.; Necciari, J.; Duret, J.P.; Gaud, C.; Decousus, H.; Boneu, B. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb. Haemost., 1998, 79, 1162-1165.
57. Siguret, V.; Pautas, E.; Février, M.; Wipff, C.; Durand-Gasselin, B., Laurent, M., Andreux, J.P.; d'Urso, M.; Gaussem, P. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): Anti-Xa and anti-IIa activities over 10 days. Thromb. Haemost., 2000, 84, 800-804.
58. Mahé, I.; Aghassarian, M.; Drouet, L.; Dit-Sollier, C.B.; Lacut, K.; Heilmann, J.J.; Mottier, D.; Bergmann, J.F. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: A comparative pharmacokinetic study. Thromb. Haemost., 2007, 97, 581-586.
59. Pautas, E.; Gouin, I.; Bellot, O.; Andreux, J.P.; Siguret, V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug. Saf., 2002, 25, 725-733
60. Tincani, E.; Mannucci, C.; Casolari, B.; Turrini, F.; Crowther, M.A.; Prisco, D.; Cenci, A.M.; Bondi, M. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: A pilot study. Haematologica, 2006, 91, 976-979.
61. Rabbat, C.G.; Cook, D.J.; Mark, A.; Crowther, B.; McDonald, E.; Clarke, F.; Meade, M.O.; Lee, K.A.; Cook, R.J. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J. Crit. Care, 2005, 20, 357-363.
62. Douketis, J.; Cook, D.; Meade, M.; Guyatt, G.; Geerts, W.; Skrobik, Y.; Albert, M.; Granton, J.; Hébert, P.; Pagliarello, G.; Marshall, J.; Fowler, R.; Freitag, A.; Rabbat, C.; Anderson, D.; Zytaruk, N.; Heels-Ansdell, D.; Crowther, M. Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and Tharmacodynamics: the DIRECT study. Arch. Intern. Med., 2008, 168, 1805-1812
63. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Ljungberg, B.; Jacobson, S.H.; Lins, L.E.; Pejler, G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane.Clin. Nephrol., 1992, 38, 97-100.
64. Sagedal, S.; Hartmann, A.; Sundstrom, K.; Bjornsen, S.; Fauchald, P.; Brosstad, F. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol. Dial. Transplant., 1999, 14, 1943-1947.
65. Klingel, R.; Schwarting, A.; Lotz, J.; Eckert, M.; Hohmann, V.; Hafner, G. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study. Kidney Blood Press. Res., 2004, 27, 211-217.
66. Lim, W.; Cook, D.J.; Crowther, M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with endstage renal failure: A meta-analysis of randomized trials. J. Am. Soc. Nephrol., 2004, 15, 3192-3206.
67. Guillet, B.; Simon, N.; Sampol, J.J.; Lorec-Penet, A.M.; Portugal, H.; Berland, Y.; Dussol, B.; Brunet, P. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol. Dial. Transplant., 2003, 18, 2348-2353.
68. Hainer, J.W.; Sherrard, D.J.; Swan, S.K.; Barrett, J.S.; Assaid, C.A.; Fossler, M.J.; Cox, D.S.; Williams, R.M.; Pittenger, A.L.; Stephenson, C.A.; Hua, T.A. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am. J. Kidney Dis., 2002, 40, 531-538.
69. Baumelou, A.; Singlas, E.; Petitclerc, T., Desmichels, D.; Jacobs, C., Soria, J. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron, 1994, 68, 202-206.
70. Fenoglio, R.; Quaglia, M.; Karvela, E.; Lazzarich, E.; Cofano, F.; Cena, T.; Musetti, C.; Pergolini, P.; Canavese, C.; Bellomo, G.; Stratta, P. Warning: Standard Doses of Low Molecular Weight Heparin exceed the upper threshold of the anti-Xa range according to the degree of Renal Failure. Nephrol. Dial. Transplant., 2007, 22, S6, vi 69.
71. Allen, N.M.; LaPointe, A.; Chen, A.Y.; Alexander, K.P.; Roe, M.T.; Pollack, C.V Jr.; Lytle, B.L.; Ohman, M.E.; Gibler, B.W., Peterson, E.D. Enoxaparin Dosing and Associated Risk of in-Hospital Bleeding and death in Patients with non-ST-Segment Elevation Acute Coronary Syndromes. Arch. Intern. Med., 2007, 167, 1539-1544.
72. Spinler, S.A.; Inverso, S.M.; Cohen, M.; Goodman, S.G.; Stringer, K.A.; Antman, E.M.; ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment. Am. Heart J., 2003, 146, 33-41.
73. Thorevska, N.; Amoateng-Adjepong, Y.; Sabahi, R.; Schiopescu I, Salloum, A.; Muralidharan, V.; Manthous, C.A. Anticoagulation in hospitalized patients with renal insufficiency. A comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest, 2004, 125, 856-863.
74. Kessler, C.M.; Esparraguera, I.M.; Jacobs, H.M.; Druy, E., Fortune, W.P.; Holloway, D.S., Giordano, J.; Davidson, BL. Monitoring the anticoagulant effects of a low molecular weight heparin preparation. Am. J. Clin. Pathol., 1995, 103, 642-648.
75. Kessler, C.M. Low molecular weight heparins: Practical considerations. Semin. Hematol., 1997, 34, 35-42.
76. Litin, S.C.; Heit, J.A.; Mees, K.A. Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: Answers to frequently asked questions. Mayo Clin. Proc., 1998, 73, 545-551.
77. Abbate, R.; Gori, A.M.; Farsi, A., Attanasio, M.; Pepe, G. Monitoring of low-molecular- weight heparins. Am. J. Cardiol., 1998, 82, 33L36L.
78. Kruse, M.W.; Lee, J.J. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am. Heart J., 2004, 148, 582-589.
79. Bastani, B.; Gonzalez, E. Prolonged anti-factor Xa level in a patient with moderate renal insufficiency receiving enoxaparin. Am. J. Nephrol,. 2002, 22, 403-404.
80. Collet, J.P.; Montalescot, G.; Choussat, R., Lison, L.; Ankri, A. Enoxaparin in unstable angina patients with renal failure. Int. J. Cardiol., 2001, 80, 81-82.
81. Hulot, J-S.; Montalescot, G.; Lechat, P.; Collet, J-P.; Ankri, A.; Urien, S. Dosing Strategy in Patients with Renal Failure Receiving Enoxaparin for the Treatment of non-ST-segment Elevation Acute Coronary Syndrome. Clin. Pharmacol. Ther., 2005, 77, 542-552.
82. Gunnarsson, P.S.; Sawyer, W.T.; Montague, D.; Williams, M.L.; Dupuis, R.E., Caiola, S M. Appropriate use of heparin: Empiric vs nomogram-based dosing. Arch. Intern. Med., 1995, 155, 526-532
83. Gosselin, R.C. Variability of Plasma Anti-Xa Activities with Different Lots of Enoxaparin. Ann. Pharmacother., 2004, 38, 563-568.
84. Kitchen, S.; Iampietro, R.; Woolley, A.M.; Preston, F.E.Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability. Thromb. Haemost., 1999, 82, 1289-1293.
85. Kovacs, M.J.; Keeney, M.; MacKinnon, K.; Boyle, E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin. Lab. Haematol., 1999, 21, 55-60.
86. Greaves, M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: On behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb. Haemostasis, 2002, 87, 163-164.
87. Alhenc-Gelas, M.; Jestin-Le Guernic, C.; Vitoux, J.F.; Kher, A.; Aiach, M.; Fiessinger, J.N. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb. Haemost., 1994, 71, 698-702.
88. Nieuwenhuis, H.K.; Albada, J.; Banga, J.D.; Sixma, J.J. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood, 1991, 78, 2337-2343.
89. Frank, R.D.; Brandenburg, V.M.; Lanzmich, R.; Floege, J. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. Nephrol. Dial. Transplant., 2004, 19, 1552-1558.
90. Crowther, M.A.; Warkentin T.E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood, 2008, 111, 4871-4879.
91. Dharmarajan, T.S.; Sohagia, A. Low-molecular-weight heparin and bleeding: How do we lower risk but maintain benefit? Ann. Intern. Med., 2006, 145, 789-790.
92. Hetzel, G.R.; Sucker, C.The heparins: All a nephrologist should know. Nephrol. Dial. Transplant., 2005, 20, 2036-2042.